Analysis of TP53 mutation status in human cancer cell lines: A reassessment

Human Mutation

Volumn 35, Issue 6, 2014, Pages 756-765

  Leroy, Bernard ^a   Girard, Luc ^b   Hollestelle, Antoinette ^c   Minna, John D ^b   Gazdar, Adi F ^b   Soussi, Thierry ^a,d  

^a SORBONNE UNIVERSITÉ   (France)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cancer cell line; Cross contamination; Misidentification; Recommendation; TP53

Indexed keywords

PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; TP53 PROTEIN, HUMAN;

BREAST CARCINOMA; CANCER CELL LINE; CARCINOMA CELL; COLORECTAL CARCINOMA; DNA DAMAGE; GENE DELETION; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RNA SEQUENCE; SHORT TANDEM REPEAT; TUMOR CELL LINE; COMPUTER PROGRAM; GENETIC DATABASE; GENETICS; INTERNET; MUTATION; NEOPLASM; PATHOLOGY;

CELL LINE, TUMOR; DATABASES, GENETIC; HUMANS; INTERNET; MUTATION; NEOPLASMS; SOFTWARE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84900989768     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22556     Document Type: Review

References (47)

1. Abaan OD, Polley EC, Davis SR, Zhu YJ, Bilke S, Walker RL, Pineda M, Gindin Y, Jiang Y, Reinhold WC, Holbeck SL, Simon RM, et al. 2013. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res 73:4372-4382.
2. American Type Culture Collection Standards Development Organization Workgroup ASN-0002. 2010. Cell line misidentification: the beginning of the end. Nat Rev Cancer 10:441-448.
3. Bajgelman MC, Strauss BE. 2006. The DU145 human prostate carcinoma cell line harbors a temperature-sensitive allele of p53. Prostate 66:1455-1462.
4. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, Reddy A, Liu M, et al. 2012. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-607.
5. Berglind H, Pawitan Y, Kato S, Ishioka C, Soussi T. 2008. Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination. Cancer Biol Ther 7:699-708.
6. Bignell GR, Greenman CD, Davies H, Butler AP, Edkins S, Andrews JM, Buck G, Chen L, Beare D, Latimer C, Widaa S, Hinton J, et al. 2010. Signatures of mutation and selection in the cancer genome. Nature 463:893-898.
7. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK, Lane DP. 2005. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 19:2122-2137.
8. Chambers AF. 2009. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res 69: 5292-5293.
9. Chow VT, Quek HH, Tock EP. 1993. Alternative splicing of the p53 tumor suppressor gene in the Molt-4 T-lymphoblastic leukemia cell line. Cancer Lett 73:141-148.
10. Christgen M, Lehmann U. 2007. MDA-MB-435: the questionable use of a melanoma cell line as a model for human breast cancer is ongoing. Cancer Biol Ther 6: 1355-1357.
11. Cottu PH, Muzeau F, Estreicher A, Flejou JF, Iggo R, Thomas G, Hamelin R. 1996. Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines. Oncogene 13:2727-2730.
12. Debernardis D, Sire EG, De Feudis P, Vikhanskaya F, Valenti M, Russo P, Parodi S, D'Incalci M, Broggini M. 1997. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 57:870-874.
13. Drexler HG, Fombonne S, Matsuo Y, Hu ZB, Hamaguchi H, Uphoff CC. 2000. p53 alterations in human leukemia-lymphoma cell lines: in vitro artifact or prerequisite for cell immortalization? Leukemia 14:198-206.
14. Dulbecco R, Vogt M. 1954. Plaque formation and isolation of pure lines with poliomyelitis viruses. J Exp Med 99:167-182.
15. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, Teague JW, Campbell PJ, et al. 2011. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39:D945-D950.
16. Gazdar AF, Girard L, Lockwood WW, Lam WL, Minna JD. 2010. Lung cancer cell lines as tools for biomedical discovery and research. J Natl Cancer Inst 102:1310-1321.
17. Gey GO, Coffman WD, Kubicke MT. 1952. Tissue culture studies of the proliferative capacity of cervical carcinoma and normal epithelium. Cancer Res 12:264-265.
18. Hauser U, Balz V, Carey TE, Grenman R, Van Lierop A, Scheckenbach K, Bier H. 2002. Reliable detection of p53 aberrations in squamous cell carcinomas of the head and neck requires transcript analysis of the entire coding region. Head Neck 24:868-873.
19. Hollestelle A, Schutte M. 2009. Comment Re: MDA-MB-435 and M14 cell lines: identical but not M14 Melanoma? Cancer Res 69:7893.
20. Ikediobi ON, Davies H, Bignell G, Edkins S, Stevens C, O'Meara S, Santarius T, Avis T, Barthorpe S, Brackenbury L, Buck G, Butler A, et al. 2006. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 5:2606-2612.
21. Isaacs WB, Carter BS, Ewing CM. 1991. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51:4716-4720.
22. Khoury MP, Marcel V, Fernandes K, Diot A, Lane DP, Bourdon JC. 2013. Detecting and quantifying p53 isoforms at mRNA level in cell lines and tissues. Methods Mol Biol 962:1-14.
23. Kropveld A, Rozemuller EH, Leppers FG, Scheidel KC, de Weger RA, Koole R, Hordijk GJ, Slootweg PJ, Tilanus MG. 1999. Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers. Lab Invest 79:347-353.
24. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, et al. 2013. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499:214-218.
25. Liscovitch M, Ravid D. 2007. A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells. Cancer Lett 245:350-352.
26. Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, Schilder RJ, Ozols RF, Testa JR. 2007. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 13:4261-4270.
27. MacLeod RA, Dirks WG, Drexler HG. 2002. Persistent use of misidentified cell lines and its prevention. Genes Chromosomes Cancer 33:103-105.
28. Marcel V, Khoury MP, Fernandes K, Diot A, Lane DP, Bourdon JC. 2013. Detecting p53 isoforms at protein level. Methods Mol Biol 962:15-29.
29. Moghaddas Gholami A, Hahne H, Wu Z, Auer FJ, Meng C, Wilhelm M, Kuster B. 2013. Global proteome analysis of the NCI-60 cell line panel. Cell Rep 4:609-620.
30. Murai Y, Hayashi S, Takahashi H, Tsuneyama K, Takano Y. 2005. Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines. Pathol Res Pract 201:109-115.
31. Nelson-Rees WA, Daniels DW, Flandermeyer RR. 1981. Cross-contamination of cells in culture. Science 212:446-452.
32. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, et al. 2006. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527.
33. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJJ, et al. 1997. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285-4300.
34. Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, Jones D, Lin ML, Beare D, Lau KW, Greenman C, Varela I, Nik-Zainal S, et al. 2010. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463:184-190.
35. Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD. 2007. MDA-MB-435 cells are derived from M14 melanoma cells-a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 104:13-19.
36. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, Lane DP. 1990. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 87:7555-7559.
37. Saeki H, Kitao H, Yoshinaga K, Nakanoko T, Kubo N, Kakeji Y, Morita M, Maehara Y. 2011. Copy-neutral loss of heterozygosity at the p53 locus in carcinogenesis of esophageal squamous cell carcinomas associated with p53 mutations. Clin Cancer Res 17:1731-1740.
38. Scudiero DA, Monks A, Sausville EA. 1998. Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen. J Natl Cancer Inst 90:862.
39. Shoemaker RH. 2006. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6:813-823.
40. Smardova J, Pavlova S, Svitakova M, Grochova D, Ravcukova B. 2005. Analysis of p53 status in human cell lines using a functional assay in yeast: detection of new non-sense p53 mutation in codon 124. Oncol Rep 14:901-907.
41. Soussi T. 2011. Advances in carcinogenesis: A historical perspective from observational studies to tumor genome sequencing and TP53 mutation spectrum analysis. Biochim Biophys Acta 1816:199-208.
42. Soussi T, Leroy B, Taschner PEM. 2014. Recommendations for analyzing and reporting TP53 gene alterations in the high throughput sequencing era. Hum Mutat, 35: 766-778.
43. Suwa H, Yoshimura T, Yamaguchi N, Kanehira K, Manabe T, Imamura M, Hiai H, Fukumoto M. 1994. K-ras and p53 alterations in genomic DNA and transcripts of human pancreatic adenocarcinoma cell lines. Jpn J Cancer Res 85:1005-1014.
44. Tada M, Iggo RD, Ishii N, Shinohe Y, Sakuma S, Estreicher A, Sawamura Y, Abe H. 1996. Clonality and stability of the p53 gene in human astrocytic tumor cells: quantitative analysis of p53 gene mutations by yeast functional assay. Int J Cancer 67:447-450.
45. Tichy A, Zaskodova D, Pejchal J, Rezacova M, Osterreicher J, Vavrova J, Cerman J. 2008. Gamma irradiation of human leukaemic cells HL-60 and MOLT-4 induces decrease in Mcl-1 and Bid, release of cytochrome c, and activation of caspase-8 and caspase-9. Int J Radiat Biol 84:523-530.
46. Wade M, Li YC, Wahl GM. 2013. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 13:83-96.
47. Wistuba II, Syed S, Behrens C, Duong M, Milchgrub S, Muller CY, Jagirdar J, Gazdar AF. 1999. Comparison of molecular changes in cervical intraepithelial neoplasia in HIV-positive and HIV-indeterminate subjects. Gynecol Oncol 74:519-526.